Loading…
Based on limited metadata with no full letter text available, this Warning Letter was issued to Wintac Limited, a drug manufacturer, on August 13, 2020. Without access to the subject line or detailed violation count, the specific regulatory concerns cannot be determined from the available information. The letter falls under FDA's drug product oversight authority, though the specific issuing office is unknown. To understand the nature and scope of violations cited, the complete Warning Letter text would need to be reviewed.